Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared t...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/4/1130 |
| _version_ | 1797570562258632704 |
|---|---|
| author | Peter Jirak Rudin Pistulli Michael Lichtenauer Bernhard Wernly Vera Paar Lukas J. Motloch Richard Rezar Christian Jung Uta C. Hoppe P. Christian Schulze Daniel Kretzschmar Rüdiger C. Braun-Dullaeus Tarek Bekfani |
| author_facet | Peter Jirak Rudin Pistulli Michael Lichtenauer Bernhard Wernly Vera Paar Lukas J. Motloch Richard Rezar Christian Jung Uta C. Hoppe P. Christian Schulze Daniel Kretzschmar Rüdiger C. Braun-Dullaeus Tarek Bekfani |
| author_sort | Peter Jirak |
| collection | DOAJ |
| description | Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (<i>p</i> < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (<i>p</i> < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (<i>p</i> < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (<i>p</i> < 0.0001) and HFpEF patients (<i>p</i> < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future. |
| first_indexed | 2024-03-10T20:27:16Z |
| format | Article |
| id | doaj.art-91ace581fbc94b2daf21604b5c0219b1 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T20:27:16Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-91ace581fbc94b2daf21604b5c0219b12023-11-19T21:42:24ZengMDPI AGJournal of Clinical Medicine2077-03832020-04-0194113010.3390/jcm9041130Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and ControlsPeter Jirak0Rudin Pistulli1Michael Lichtenauer2Bernhard Wernly3Vera Paar4Lukas J. Motloch5Richard Rezar6Christian Jung7Uta C. Hoppe8P. Christian Schulze9Daniel Kretzschmar10Rüdiger C. Braun-Dullaeus11Tarek Bekfani12Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDivision of Vascular Medicine, Department of Cardiology and Angiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Munster, North Rhine-Westphalia, 48149 Münster, GermanyClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDivision of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, 40225 Duesseldorf, GermanyClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, AustriaDepartment of Internal Medicine I, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Friedrich Schiller University Jena, 07740 Jena, GermanyDepartment of Internal Medicine I, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Friedrich Schiller University Jena, 07740 Jena, GermanyDepartment of Internal Medicine I, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Magdeburg, Otto von Gericke University, Magdeburg, 39120 Magdeburg, GermanyDepartment of Internal Medicine I, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Magdeburg, Otto von Gericke University, Magdeburg, 39120 Magdeburg, GermanyBackground: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (<i>p</i> < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (<i>p</i> < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (<i>p</i> < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (<i>p</i> < 0.0001) and HFpEF patients (<i>p</i> < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future.https://www.mdpi.com/2077-0383/9/4/1130HFpEFheart failureHFrEFbiomarkersST2suPAR |
| spellingShingle | Peter Jirak Rudin Pistulli Michael Lichtenauer Bernhard Wernly Vera Paar Lukas J. Motloch Richard Rezar Christian Jung Uta C. Hoppe P. Christian Schulze Daniel Kretzschmar Rüdiger C. Braun-Dullaeus Tarek Bekfani Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls Journal of Clinical Medicine HFpEF heart failure HFrEF biomarker sST2 suPAR |
| title | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
| title_full | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
| title_fullStr | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
| title_full_unstemmed | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
| title_short | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
| title_sort | expression of the novel cardiac biomarkers sst2 gdf 15 supar and h fabp in hfpef patients compared to icm dcm and controls |
| topic | HFpEF heart failure HFrEF biomarker sST2 suPAR |
| url | https://www.mdpi.com/2077-0383/9/4/1130 |
| work_keys_str_mv | AT peterjirak expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT rudinpistulli expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT michaellichtenauer expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT bernhardwernly expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT verapaar expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT lukasjmotloch expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT richardrezar expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT christianjung expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT utachoppe expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT pchristianschulze expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT danielkretzschmar expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT rudigercbraundullaeus expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols AT tarekbekfani expressionofthenovelcardiacbiomarkerssst2gdf15suparandhfabpinhfpefpatientscomparedtoicmdcmandcontrols |